comprehensive -WSS

comprehensive

author：focus 2025-09-30 22:06:27 - browse：52452

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Teladoc has a new CEO, but challenges remain the same

entertainment

focus

WSS

Stephen Quake on the Chan Zuckerberg quest to conquer disease

My yearlong odyssey to get my son’s ADHD medication covered

ALS patient reclaims some autonomy thanks to wearable 'robot'

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

hotspot

comprehensive

hotspot

In Memoriam: Notable people who died in 2023

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Drug repurposing or repositioning? The language matters

How faith leaders like me can help address America's obesity epidemic

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How digital therapeutics firms are pivoting after Pear's bankruptcy

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Biotech venture capitalists face new demands from investors

In Memoriam: Notable people who died in 2023

Lilly's Alzheimer's drug donanemab backed by FDA advisers

hotspot

AI generated plenty of interest at JPM but not a lot of trust

My yearlong odyssey to get my son’s ADHD medication covered

Parkinson’s finding may lead to tests and, someday, treatments

Biotech venture capitalists face new demands from investors

Curing rare childhood diseases will falter unless Congress steps up

Stephen Quake on the Chan Zuckerberg quest to conquer disease

entertainment

hotspot

focus

focus